Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients
Aim: To compare the outcomes of GDPT [gemcitabine (G), cisplatin (D), prednisone (P), thalidomide (T)] versus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in treating newly diagnosed PTCL (peripheral T-cell lymphoma). Methods: An open-label prospective clinical trial with 153 newly...
Gespeichert in:
| Veröffentlicht in: | Therapeutic advances in medical oncology 2020, Vol.12, p.1758835920923829 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 1758835920923829 |
| container_title | Therapeutic advances in medical oncology |
| container_volume | 12 |
| creator | Sun, Yuanyuan Li, Ling Li, Xin Zhang, Lei Wang, Xinhua Fu, Xiaorui Sun, Zhenchang Zhang, Xudong Li, Zhaoming Wu, Jingjing Yu, Hui Chang, Yu Yan, Jiaqin Wu, Xiaolong Zhou, Zhiyuan Nan, Feifei Tian, Li Zhang, Mingzhi |
| description | Aim:
To compare the outcomes of GDPT [gemcitabine (G), cisplatin (D), prednisone (P), thalidomide (T)] versus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in treating newly diagnosed PTCL (peripheral T-cell lymphoma).
Methods:
An open-label prospective clinical trial with 153 newly diagnosed PTCL patients conducted between January 2010 and December 2018 was designed. Patients were randomly assigned to the GDPT (77 cases) and CHOP (76 cases) groups. Patients in each group were further divided into four subgroups: PTCL, not otherwise specified (PTCL-NOS); anaplastic large cell lymphoma (ALCL), angioimmunoblastic T cell lymphoma (AITL), and other types subgroup, in accordance with pathological patterns. Based on expression of RRM1, TOP2A, TUBB3, and ERCC1, patients were divided into groups with high and low gene expression levels. Clinical characteristics, side effects, efficacy, progression-free survival (PFS), and overall survival (OS) were compared.
Results:
There were no significant differences in the basic clinical features or side effects between the GDPT and CHOP groups. The overall response rate (ORR) of the GDPT group was better than that of the CHOP group (66.3% versus 50.0%, p = 0.042), as was the complete remission (CR) rate (42.9% versus 27.6%, p = 0.049). Patients in the GDPT group had a longer PFS and OS than the CHOP group. The 4-year PFS and OS rates in the GDPT group were both superior to those in the CHOP group (63.6% versus 53.0% for PFS, p = 0.035; 66.8% versus 53.6% for OS, p = 0.039). In the GDPT group, the difference in CR between the four subgroups was statistically significant (p = 0.046). In the CHOP group, differences in both CR and ORR among the four subgroups were statistically significant (p |
| doi_str_mv | 10.1177/1758835920923829 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7278096</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1758835920923829</sage_id><sourcerecordid>2415287580</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-68cd4b962ff6abc7fccd78ec98bacca67822e7dbaea24ca586e1babf5caeb5de3</originalsourceid><addsrcrecordid>eNp1kU9v1DAQxSMEoqVw54QscSlSUxxv7DgXJLRAi1Rpe1jO0die7LpK7GAnrfYD9HvjaPuPSj3ZGv_mzTy_LPtY0NOiqKqvRcWlXPCa0ZotJKtfZYdzKZ9rr5_cD7J3MV5RKkQp6NvsYME4p1KUh9ntahq17zES35KzH5drcrzBXtsRlHV4QrSNQwejdSdkCGicjX4uj1vorPG9NfiFXGOIUyTL89UlsY44vOl2xFjYOB_RkAGDHbYYoCPrXGPXkW7XD1vfAxmSMroxvs_etNBF_HB3HmV_fv1cL8_zi9XZ7-X3i1yXgo25kNqUqhasbQUoXbVam0qirqUCrUFUkjGsjAIEVmrgUmChQLVcAypucHGUfdvrDpPq0eg0O63VDMH2EHaNB9v8_-Lsttn466ZilaS1SALHdwLB_50wjk1v4-wJHPopNqwsOJPp22lCPz9Dr_wUXLKXKFaXIiXIE0X3lA4-xoDtwzIFbeaMm-cZp5ZPT008NNyHmoB8D0TY4OPUFwX_AWZ8stk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2429461175</pqid></control><display><type>article</type><title>Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients</title><source>DOAJ Directory of Open Access Journals</source><source>Sage Journals GOLD Open Access 2024</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Sun, Yuanyuan ; Li, Ling ; Li, Xin ; Zhang, Lei ; Wang, Xinhua ; Fu, Xiaorui ; Sun, Zhenchang ; Zhang, Xudong ; Li, Zhaoming ; Wu, Jingjing ; Yu, Hui ; Chang, Yu ; Yan, Jiaqin ; Wu, Xiaolong ; Zhou, Zhiyuan ; Nan, Feifei ; Tian, Li ; Zhang, Mingzhi</creator><creatorcontrib>Sun, Yuanyuan ; Li, Ling ; Li, Xin ; Zhang, Lei ; Wang, Xinhua ; Fu, Xiaorui ; Sun, Zhenchang ; Zhang, Xudong ; Li, Zhaoming ; Wu, Jingjing ; Yu, Hui ; Chang, Yu ; Yan, Jiaqin ; Wu, Xiaolong ; Zhou, Zhiyuan ; Nan, Feifei ; Tian, Li ; Zhang, Mingzhi</creatorcontrib><description>Aim:
To compare the outcomes of GDPT [gemcitabine (G), cisplatin (D), prednisone (P), thalidomide (T)] versus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in treating newly diagnosed PTCL (peripheral T-cell lymphoma).
Methods:
An open-label prospective clinical trial with 153 newly diagnosed PTCL patients conducted between January 2010 and December 2018 was designed. Patients were randomly assigned to the GDPT (77 cases) and CHOP (76 cases) groups. Patients in each group were further divided into four subgroups: PTCL, not otherwise specified (PTCL-NOS); anaplastic large cell lymphoma (ALCL), angioimmunoblastic T cell lymphoma (AITL), and other types subgroup, in accordance with pathological patterns. Based on expression of RRM1, TOP2A, TUBB3, and ERCC1, patients were divided into groups with high and low gene expression levels. Clinical characteristics, side effects, efficacy, progression-free survival (PFS), and overall survival (OS) were compared.
Results:
There were no significant differences in the basic clinical features or side effects between the GDPT and CHOP groups. The overall response rate (ORR) of the GDPT group was better than that of the CHOP group (66.3% versus 50.0%, p = 0.042), as was the complete remission (CR) rate (42.9% versus 27.6%, p = 0.049). Patients in the GDPT group had a longer PFS and OS than the CHOP group. The 4-year PFS and OS rates in the GDPT group were both superior to those in the CHOP group (63.6% versus 53.0% for PFS, p = 0.035; 66.8% versus 53.6% for OS, p = 0.039). In the GDPT group, the difference in CR between the four subgroups was statistically significant (p = 0.046). In the CHOP group, differences in both CR and ORR among the four subgroups were statistically significant (p < 0.001 and p = 0.005, respectively). There were also statistically significant differences in CR between patients treated with CHOP and GDPT in the PTCL-NOS subgroup, AITL subgroup, and the other types subgroup (p = 0.015; p = 0.003; p = 0.005, respectively). The data also showed a significant difference in OS among the four subgroups within the GDPT group (p = 0.001). The OS of AITL was shorter than that of the other three subgroups. Four subgroups of CHOP showed a significant difference in PFS (p = 0.019). There was no statistical association between responses and the gene expression levels of RRM1, ERCC1, TUBB3, and TOP2A.
Conclusion:
The GDPT group had better response rates and prolonged patient PFS and OS. As a promising new regimen, GDPT is expected to become the first-line therapy for PTCL. New agents should be applied to patients who do not achieve good responses with previous treatment, such as those diagnosed with angioimmunoblastic T cell lymphoma.
Trial registration:
This open randomized prospective clinical trial was registered at ClinicalTrials.gov (NCT01664975).</description><identifier>ISSN: 1758-8359</identifier><identifier>ISSN: 1758-8340</identifier><identifier>EISSN: 1758-8359</identifier><identifier>DOI: 10.1177/1758835920923829</identifier><identifier>PMID: 32550864</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Anaplastic large-cell lymphoma ; Chemotherapy ; Cisplatin ; Clinical trials ; Cyclophosphamide ; Doxorubicin ; ERCC1 protein ; Gemcitabine ; Gene expression ; Lymphocytes T ; Lymphoma ; Original Research ; Patients ; Prednisone ; Remission ; Side effects ; Statistical analysis ; T-cell lymphoma ; Thalidomide ; Vincristine</subject><ispartof>Therapeutic advances in medical oncology, 2020, Vol.12, p.1758835920923829</ispartof><rights>The Author(s), 2020</rights><rights>The Author(s), 2020.</rights><rights>The Author(s), 2020. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s), 2020 2020 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-68cd4b962ff6abc7fccd78ec98bacca67822e7dbaea24ca586e1babf5caeb5de3</citedby><cites>FETCH-LOGICAL-c462t-68cd4b962ff6abc7fccd78ec98bacca67822e7dbaea24ca586e1babf5caeb5de3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278096/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278096/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,4022,21964,27851,27921,27922,27923,44943,45331,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32550864$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sun, Yuanyuan</creatorcontrib><creatorcontrib>Li, Ling</creatorcontrib><creatorcontrib>Li, Xin</creatorcontrib><creatorcontrib>Zhang, Lei</creatorcontrib><creatorcontrib>Wang, Xinhua</creatorcontrib><creatorcontrib>Fu, Xiaorui</creatorcontrib><creatorcontrib>Sun, Zhenchang</creatorcontrib><creatorcontrib>Zhang, Xudong</creatorcontrib><creatorcontrib>Li, Zhaoming</creatorcontrib><creatorcontrib>Wu, Jingjing</creatorcontrib><creatorcontrib>Yu, Hui</creatorcontrib><creatorcontrib>Chang, Yu</creatorcontrib><creatorcontrib>Yan, Jiaqin</creatorcontrib><creatorcontrib>Wu, Xiaolong</creatorcontrib><creatorcontrib>Zhou, Zhiyuan</creatorcontrib><creatorcontrib>Nan, Feifei</creatorcontrib><creatorcontrib>Tian, Li</creatorcontrib><creatorcontrib>Zhang, Mingzhi</creatorcontrib><title>Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients</title><title>Therapeutic advances in medical oncology</title><addtitle>Ther Adv Med Oncol</addtitle><description>Aim:
To compare the outcomes of GDPT [gemcitabine (G), cisplatin (D), prednisone (P), thalidomide (T)] versus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in treating newly diagnosed PTCL (peripheral T-cell lymphoma).
Methods:
An open-label prospective clinical trial with 153 newly diagnosed PTCL patients conducted between January 2010 and December 2018 was designed. Patients were randomly assigned to the GDPT (77 cases) and CHOP (76 cases) groups. Patients in each group were further divided into four subgroups: PTCL, not otherwise specified (PTCL-NOS); anaplastic large cell lymphoma (ALCL), angioimmunoblastic T cell lymphoma (AITL), and other types subgroup, in accordance with pathological patterns. Based on expression of RRM1, TOP2A, TUBB3, and ERCC1, patients were divided into groups with high and low gene expression levels. Clinical characteristics, side effects, efficacy, progression-free survival (PFS), and overall survival (OS) were compared.
Results:
There were no significant differences in the basic clinical features or side effects between the GDPT and CHOP groups. The overall response rate (ORR) of the GDPT group was better than that of the CHOP group (66.3% versus 50.0%, p = 0.042), as was the complete remission (CR) rate (42.9% versus 27.6%, p = 0.049). Patients in the GDPT group had a longer PFS and OS than the CHOP group. The 4-year PFS and OS rates in the GDPT group were both superior to those in the CHOP group (63.6% versus 53.0% for PFS, p = 0.035; 66.8% versus 53.6% for OS, p = 0.039). In the GDPT group, the difference in CR between the four subgroups was statistically significant (p = 0.046). In the CHOP group, differences in both CR and ORR among the four subgroups were statistically significant (p < 0.001 and p = 0.005, respectively). There were also statistically significant differences in CR between patients treated with CHOP and GDPT in the PTCL-NOS subgroup, AITL subgroup, and the other types subgroup (p = 0.015; p = 0.003; p = 0.005, respectively). The data also showed a significant difference in OS among the four subgroups within the GDPT group (p = 0.001). The OS of AITL was shorter than that of the other three subgroups. Four subgroups of CHOP showed a significant difference in PFS (p = 0.019). There was no statistical association between responses and the gene expression levels of RRM1, ERCC1, TUBB3, and TOP2A.
Conclusion:
The GDPT group had better response rates and prolonged patient PFS and OS. As a promising new regimen, GDPT is expected to become the first-line therapy for PTCL. New agents should be applied to patients who do not achieve good responses with previous treatment, such as those diagnosed with angioimmunoblastic T cell lymphoma.
Trial registration:
This open randomized prospective clinical trial was registered at ClinicalTrials.gov (NCT01664975).</description><subject>Anaplastic large-cell lymphoma</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>Clinical trials</subject><subject>Cyclophosphamide</subject><subject>Doxorubicin</subject><subject>ERCC1 protein</subject><subject>Gemcitabine</subject><subject>Gene expression</subject><subject>Lymphocytes T</subject><subject>Lymphoma</subject><subject>Original Research</subject><subject>Patients</subject><subject>Prednisone</subject><subject>Remission</subject><subject>Side effects</subject><subject>Statistical analysis</subject><subject>T-cell lymphoma</subject><subject>Thalidomide</subject><subject>Vincristine</subject><issn>1758-8359</issn><issn>1758-8340</issn><issn>1758-8359</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp1kU9v1DAQxSMEoqVw54QscSlSUxxv7DgXJLRAi1Rpe1jO0die7LpK7GAnrfYD9HvjaPuPSj3ZGv_mzTy_LPtY0NOiqKqvRcWlXPCa0ZotJKtfZYdzKZ9rr5_cD7J3MV5RKkQp6NvsYME4p1KUh9ntahq17zES35KzH5drcrzBXtsRlHV4QrSNQwejdSdkCGicjX4uj1vorPG9NfiFXGOIUyTL89UlsY44vOl2xFjYOB_RkAGDHbYYoCPrXGPXkW7XD1vfAxmSMroxvs_etNBF_HB3HmV_fv1cL8_zi9XZ7-X3i1yXgo25kNqUqhasbQUoXbVam0qirqUCrUFUkjGsjAIEVmrgUmChQLVcAypucHGUfdvrDpPq0eg0O63VDMH2EHaNB9v8_-Lsttn466ZilaS1SALHdwLB_50wjk1v4-wJHPopNqwsOJPp22lCPz9Dr_wUXLKXKFaXIiXIE0X3lA4-xoDtwzIFbeaMm-cZp5ZPT008NNyHmoB8D0TY4OPUFwX_AWZ8stk</recordid><startdate>2020</startdate><enddate>2020</enddate><creator>Sun, Yuanyuan</creator><creator>Li, Ling</creator><creator>Li, Xin</creator><creator>Zhang, Lei</creator><creator>Wang, Xinhua</creator><creator>Fu, Xiaorui</creator><creator>Sun, Zhenchang</creator><creator>Zhang, Xudong</creator><creator>Li, Zhaoming</creator><creator>Wu, Jingjing</creator><creator>Yu, Hui</creator><creator>Chang, Yu</creator><creator>Yan, Jiaqin</creator><creator>Wu, Xiaolong</creator><creator>Zhou, Zhiyuan</creator><creator>Nan, Feifei</creator><creator>Tian, Li</creator><creator>Zhang, Mingzhi</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>AFRWT</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2020</creationdate><title>Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients</title><author>Sun, Yuanyuan ; Li, Ling ; Li, Xin ; Zhang, Lei ; Wang, Xinhua ; Fu, Xiaorui ; Sun, Zhenchang ; Zhang, Xudong ; Li, Zhaoming ; Wu, Jingjing ; Yu, Hui ; Chang, Yu ; Yan, Jiaqin ; Wu, Xiaolong ; Zhou, Zhiyuan ; Nan, Feifei ; Tian, Li ; Zhang, Mingzhi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-68cd4b962ff6abc7fccd78ec98bacca67822e7dbaea24ca586e1babf5caeb5de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Anaplastic large-cell lymphoma</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>Clinical trials</topic><topic>Cyclophosphamide</topic><topic>Doxorubicin</topic><topic>ERCC1 protein</topic><topic>Gemcitabine</topic><topic>Gene expression</topic><topic>Lymphocytes T</topic><topic>Lymphoma</topic><topic>Original Research</topic><topic>Patients</topic><topic>Prednisone</topic><topic>Remission</topic><topic>Side effects</topic><topic>Statistical analysis</topic><topic>T-cell lymphoma</topic><topic>Thalidomide</topic><topic>Vincristine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sun, Yuanyuan</creatorcontrib><creatorcontrib>Li, Ling</creatorcontrib><creatorcontrib>Li, Xin</creatorcontrib><creatorcontrib>Zhang, Lei</creatorcontrib><creatorcontrib>Wang, Xinhua</creatorcontrib><creatorcontrib>Fu, Xiaorui</creatorcontrib><creatorcontrib>Sun, Zhenchang</creatorcontrib><creatorcontrib>Zhang, Xudong</creatorcontrib><creatorcontrib>Li, Zhaoming</creatorcontrib><creatorcontrib>Wu, Jingjing</creatorcontrib><creatorcontrib>Yu, Hui</creatorcontrib><creatorcontrib>Chang, Yu</creatorcontrib><creatorcontrib>Yan, Jiaqin</creatorcontrib><creatorcontrib>Wu, Xiaolong</creatorcontrib><creatorcontrib>Zhou, Zhiyuan</creatorcontrib><creatorcontrib>Nan, Feifei</creatorcontrib><creatorcontrib>Tian, Li</creatorcontrib><creatorcontrib>Zhang, Mingzhi</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Therapeutic advances in medical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sun, Yuanyuan</au><au>Li, Ling</au><au>Li, Xin</au><au>Zhang, Lei</au><au>Wang, Xinhua</au><au>Fu, Xiaorui</au><au>Sun, Zhenchang</au><au>Zhang, Xudong</au><au>Li, Zhaoming</au><au>Wu, Jingjing</au><au>Yu, Hui</au><au>Chang, Yu</au><au>Yan, Jiaqin</au><au>Wu, Xiaolong</au><au>Zhou, Zhiyuan</au><au>Nan, Feifei</au><au>Tian, Li</au><au>Zhang, Mingzhi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients</atitle><jtitle>Therapeutic advances in medical oncology</jtitle><addtitle>Ther Adv Med Oncol</addtitle><date>2020</date><risdate>2020</risdate><volume>12</volume><spage>1758835920923829</spage><pages>1758835920923829-</pages><issn>1758-8359</issn><issn>1758-8340</issn><eissn>1758-8359</eissn><abstract>Aim:
To compare the outcomes of GDPT [gemcitabine (G), cisplatin (D), prednisone (P), thalidomide (T)] versus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in treating newly diagnosed PTCL (peripheral T-cell lymphoma).
Methods:
An open-label prospective clinical trial with 153 newly diagnosed PTCL patients conducted between January 2010 and December 2018 was designed. Patients were randomly assigned to the GDPT (77 cases) and CHOP (76 cases) groups. Patients in each group were further divided into four subgroups: PTCL, not otherwise specified (PTCL-NOS); anaplastic large cell lymphoma (ALCL), angioimmunoblastic T cell lymphoma (AITL), and other types subgroup, in accordance with pathological patterns. Based on expression of RRM1, TOP2A, TUBB3, and ERCC1, patients were divided into groups with high and low gene expression levels. Clinical characteristics, side effects, efficacy, progression-free survival (PFS), and overall survival (OS) were compared.
Results:
There were no significant differences in the basic clinical features or side effects between the GDPT and CHOP groups. The overall response rate (ORR) of the GDPT group was better than that of the CHOP group (66.3% versus 50.0%, p = 0.042), as was the complete remission (CR) rate (42.9% versus 27.6%, p = 0.049). Patients in the GDPT group had a longer PFS and OS than the CHOP group. The 4-year PFS and OS rates in the GDPT group were both superior to those in the CHOP group (63.6% versus 53.0% for PFS, p = 0.035; 66.8% versus 53.6% for OS, p = 0.039). In the GDPT group, the difference in CR between the four subgroups was statistically significant (p = 0.046). In the CHOP group, differences in both CR and ORR among the four subgroups were statistically significant (p < 0.001 and p = 0.005, respectively). There were also statistically significant differences in CR between patients treated with CHOP and GDPT in the PTCL-NOS subgroup, AITL subgroup, and the other types subgroup (p = 0.015; p = 0.003; p = 0.005, respectively). The data also showed a significant difference in OS among the four subgroups within the GDPT group (p = 0.001). The OS of AITL was shorter than that of the other three subgroups. Four subgroups of CHOP showed a significant difference in PFS (p = 0.019). There was no statistical association between responses and the gene expression levels of RRM1, ERCC1, TUBB3, and TOP2A.
Conclusion:
The GDPT group had better response rates and prolonged patient PFS and OS. As a promising new regimen, GDPT is expected to become the first-line therapy for PTCL. New agents should be applied to patients who do not achieve good responses with previous treatment, such as those diagnosed with angioimmunoblastic T cell lymphoma.
Trial registration:
This open randomized prospective clinical trial was registered at ClinicalTrials.gov (NCT01664975).</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>32550864</pmid><doi>10.1177/1758835920923829</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1758-8359 |
| ispartof | Therapeutic advances in medical oncology, 2020, Vol.12, p.1758835920923829 |
| issn | 1758-8359 1758-8340 1758-8359 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7278096 |
| source | DOAJ Directory of Open Access Journals; Sage Journals GOLD Open Access 2024; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Anaplastic large-cell lymphoma Chemotherapy Cisplatin Clinical trials Cyclophosphamide Doxorubicin ERCC1 protein Gemcitabine Gene expression Lymphocytes T Lymphoma Original Research Patients Prednisone Remission Side effects Statistical analysis T-cell lymphoma Thalidomide Vincristine |
| title | Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T00%3A14%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20of%20GDPT%20(gemcitabine,%20cisplatin,%20prednisone,%20thalidomide)%20versus%20CHOP%20in%20newly%20diagnosed%20peripheral%20T-cell%20lymphoma%20patients&rft.jtitle=Therapeutic%20advances%20in%20medical%20oncology&rft.au=Sun,%20Yuanyuan&rft.date=2020&rft.volume=12&rft.spage=1758835920923829&rft.pages=1758835920923829-&rft.issn=1758-8359&rft.eissn=1758-8359&rft_id=info:doi/10.1177/1758835920923829&rft_dat=%3Cproquest_pubme%3E2415287580%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2429461175&rft_id=info:pmid/32550864&rft_sage_id=10.1177_1758835920923829&rfr_iscdi=true |